期刊文献+

大剂量他汀强化降脂治疗更多获益及逆转斑块的研究进展 被引量:7

A Review of Recent Advances in Plaque Regression with High-Dose Statin Therapy
下载PDF
导出
摘要 近年来多项临床试验证实了他汀强化降脂治疗较之常规降脂治疗具有更显著的临床获益,并且强化降脂治疗能够延缓动脉粥样硬化斑块进展,甚至逆转斑块。现综述近年来有关他汀强化降脂更多获益及逆转斑块的证据,并进一步探讨有关"thelower,the better"的结论的临床应用及他汀逆转斑块的相关机制。 Many studies have investigated the efficacy and safety of statin therapy with more aggressive lipid lowering. These studies have confirmed that there are clinical benefits and plaque regression. This review is a brief overview of recent, large-scale, randomized, pla- cebo and active controlled trials of statin therapy with more aggressive lipid lowering, a discussion of "the lower, the better" and its usable condition, and the regression of coronary atherosclerosis.
作者 张超伟 刘滨
出处 《心血管病学进展》 CAS 2012年第6期758-762,共5页 Advances in Cardiovascular Diseases
关键词 强化降脂 他汀 有效性 安全性 斑块逆转 炎症 aggressive lowering of LDL statin efficacy safety plaque regression inflammation
  • 相关文献

参考文献35

  • 1Cbolesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials [ J ]. Lancet, 2010,376 ( 9753 ) : 1670-1681.
  • 2Reiner Z, Catapano AL, de Backer G, et al. ESC/EAS guidelines for the man- agement of dyslipidaemias[ J]. Eur Heart J,2011,32(14) :1769-1818.
  • 3Rallidis LS, Kotakos C, Sourides V, et al. Attainment of optional low-density lipoprotein cholesterol goal of less than 70 mg/dl and impact on prognosis of very high risk stable coronary patients: a 3-year follow-up [ J ]. Expert Opin Pharma-eother,2011,12(10):1481-1489.
  • 4Nicholls SJ, Brandrup-Wognsen G, Palmer M, et al. Meta-analysis of compara- tive efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvas- tatin on lowering levels of atherogenic lipids (from VOYAGER) [J]. Am J Car- diol,2010,105 ( 1 ) :69-76.
  • 5Sakamoto T, Ogawa H. "Just make it lower" is an alternative strategy of lipid- lowering therapy with statins in Japanese patients [ J ]. Circ J, 2010,74 ( 8 ) : 1731-1741.
  • 6http ://www. fda. gov/Drugs/DrugSafety/ucm293101. htm.
  • 7吴陈璐,赵水平.他汀类药物引起的相关性肌病不良反应研究现状[J].中国药学杂志,2011,46(11):872-874. 被引量:8
  • 8Martin S, Blumenthal R, Miner M. LDL cholesterol: the lower the better[ J]. Med Clin N Am,2012,96( 1 ) :13-26.
  • 9Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease E- valuation ( GREACE ) Study: a post-hoc analysis [ J ]. Lancet, 2010, 376 (9756) : 1916 -1922.
  • 10Cohen DE, Anania FA, Chalasani N, et al. An assessment of statin safety by hepatologists [ J ]. Am J Cardiol, 2006,97 ( 8A ) :77 C-81C.

二级参考文献63

  • 1Steven E. Nissen,Stephen J. Nicholls,Ilks Sipahi,Peter Libby,Joel S. Raichlen,Christie M. Ballantyne,Jean Davignon,Raimund Erbel,Jean Charles Fruchart,Jean-Claude Tardif,Paul Schoenhagen,Tim Crowe,Valerie Cain,Kathy Wolski,Marlene Coormastic,E. Murat Tuzcu,仝其广(译),王淑敏(译),胡大一(校).极高强度他汀治疗对冠状动脉粥样硬化消退的影响——ASTEROID试验[J].美国医学会杂志(中文版),2006,25(4):215-223. 被引量:344
  • 2中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5222
  • 3JOY T R, HEGELE R A. Narrative review : statin-related myopathy [J]. Ann Intern Med, 2009,150(12) :858-868.
  • 4BRucKERT E, HAYEM G, DEJAGER S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyper- lipidemic patients - The PRIMO Study [ J]. Cardiovasc Drugs Ther, 2005,19(6) :403-414.
  • 5MOLOKHIAL M, MCKEIGUE P, CURCIN V, et al. Statin induced myopathy and myalgia: Time trend analysis and comparison of risk associated with statin class from 1991-2006 [J]. PLoS One, 2008 ,3(6) :2522.
  • 6GOUNDEN R, BLOCKMAN M. Statin-induced myopathy [J]. Cardiovasc J Afr . 2008,19(3) :156-157.
  • 7MRC/BHF HEART PROTECTION STUDY COLLABORATIVE GROUP, ARMITAGE J, BOWMAN L, et al. Effects of simvastatin 40 rag daily on muscle and liver adverse effects in a 5-year randomized placebo- controlled trial in 20,536 high-risk people [ J ]. BMC Clin Pharmacol, 2009, 9:6.
  • 8KAPUR N K, MUSUNURU K. Clinical efficiency and safety of statins in managing cardiovascular risk [J]. Vase Health Risk Manag,2008,4( 2 ) :341-353.
  • 9OWCZAREK J, JASNSKA M, ORSZULAK-MICHALAK D. Druginduced myopathies. An overview of the possible mechanisms [ J]. Pharmacol Rep ,2005,57 ( 1 ) :23-34.
  • 10SILVA M, MATTHEWS M L, JARVIS C, et al. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy [J]. Clin Ther, 2007,29(2):253-260.

共引文献49

同被引文献88

引证文献7

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部